A review of genetic alterations in the serotonin pathway and their correlation with psychotic diseases and response to atypical antipsychotics

Schizophrenia Research

Volumn 170, Issue 1, 2016, Pages 18-29

  Baou, Maria ^a   Boumba, Vassiliki A ^a   Petrikis, Petros ^b   Rallis, Georgios ^a   Vougiouklakis, Theodore ^a   Mavreas, Venetsanos ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Atypical antipsychotics; Genetic alterations; Review; Serotonin; Serotonin pathway; SNPs

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; OLANZAPINE; PEROSPIRONE; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; NEUROLEPTIC AGENT;

AMINO ACID SEQUENCE; BIPOLAR DISORDER; DNA POLYMORPHISM; ETHNICITY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 84948823732     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.11.003     Document Type: Review

References (227)

1. Abdolmaleky H.M., Nohesara S., Ghadirivasfi M., Lambert A.W., Ahmadkhaniha H., Ozturk S., et al. DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia. Schizophr. Res. 2014, 152(2-3):373-380.
2. Abdolmaleky H.M., Yaqubi S., Papageorgis P., Lambert A.W., Ozturk S., Sivaraman V., et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr. Res. 2011, 129(2-3):183-190.
3. Abdolmaleky H.M., Faraone S.V., Glatt S.J., Tsuang M.T. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr. Res. 2004, 67(1):53-62.
4. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 2007, 78:133-164.
5. Alfimova M.V., Monakhov M.V., Abramova L.I., Golubev S.A., Golimbet V.E. Polymorphism of serotonin receptor genes (5-HTR2A) and dysbindin (DTNBP1) and individual components of short-term verbal memory processes in schizophrenia. Neurosci. Behav. Physiol. 2010, 40(8):934-940.
6. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40(7):827-834.
7. Anttila S., Kampman O., Illi A., Rontu R., Lehtimäki T., Leinonen E. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 2007, 7:22.
8. Araga U.S., Narasu M.L. Association between the 102T/C polymorphism of serotonin-2A receptor gene and schizophrenia among south Indians. Mol. Psychiatry 2002, 7(6):540-541.
9. Arias B., Collier D.A., Gastó C., Pintor L., Gutiérrez B., Vallès V., et al. Genetic variation in the 5-HT5A receptor gene in patients with bipolar disorder and major depression. Neurosci. Lett. 2001, 303(2):111-114.
10. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., et al. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355(9215):1615-1616.
11. Arranz M.J., Bolonna A.A., Munro J., Curtis C.J., Collier D.A., Kerwin R.W. The serotonin transporter and clozapine response. Mol. Psychiatry 2000, 5(2):124-125.
12. Arranz M.J., Munro J., Sham P., Kirov G., Murray R.M., Collier D.A., et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 1998, 32(2):93-99.
13. Arranz M.J., Munro J., Owen M.J., Spurlock G., Sham P.C., Zhao J., et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry 1998, 3(1):61-66.
14. Arranz M.J., Erdmann J., Kirov G., Rietschel M., Sodhi M., Albus M., et al. 5-HT2A receptor and bipolar affective disorder: association studies in affected patients. Neurosci. Lett. 1997, 224(2):95-98.
15. Arranz M.J., Collier D.A., Munro J., Sham P., Kirov G., Sodhi M., et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci. Lett. 1996, 217(2-3):177-178.
16. Amato D. Serotonin in antipsychotic drugs action. Behav. Brain Res. 2015, 277:125-135.
17. Bai Y.M., Chen T.T., Liou Y.J., Hong C.J., Tsai S.J. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr. Res. 2011, 125(2-3):179-186.
18. Baritaki S., Rizos E., Zafiropoulos A., Soufla G., Katsafouros K., Gourvas V., et al. Association between schizophrenia and DRD3 or HTR2 receptor gene variants. Eur. J. Hum. Genet. 2004, 12(7):535-541.
19. Basile V.S., Masellis M., De Luca V., Meltzer H.Y., Kennedy J.L. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360(9347):1790-1791.
20. Bellivier F., Leroux M., Henry C., Rayah F., Rouillon F., Laplanche J.L., et al. Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neurosci. Lett. 2002, 334(1):17-20.
21. Bellivier F., Henry C., Szöke A., Schürhoff F., Nosten-Bertrand M., Feingold J., et al. Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci. Lett. 1998, 255(3):143-146.
22. Bellivier F., Leboyer M., Courtet P., Buresi C., Beaufils B., Samolyk D., et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch. Gen. Psychiatry 1998, 55(1):33-37.
23. Bellivier F., Laplanche J.L., Leboyer M., Feingold J., Bottos C., Allilaire J.F., et al. Serotonin transporter gene and manic depressive illness: an association study. Biol. Psychiatry 1997, 41(6):750-752.
24. Birkett J.T., Arranz M.J., Munro J., Osbourn S., Kerwin R.W., Collier D.A. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000, 11(9):2017-2020.
25. Bockaert J., Claeysen S., Bécamel C., Dumuis A., Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006, 326(2):553-572.
26. Bosia M., Lorenzi C., Pirovano A., Guglielmino C., Cocchi F., Spangaro M., et al. COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics 2015, 16(1):35-44.
27. Brüss M., Kiel S., Bönisch H., Kostanian A., Göthert M. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor. Neurochem. Int. 2005, 47(3):196-203.
28. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996, 15(5):442-455.
29. Castensson A., Emilsson L., Sundberg R., Jazin E. Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biol. Psychiatry 2003, 54(11):1212-1221.
30. Chen S.F., Shen Y.C., Chen C.H. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology 2009, 205(2):285-292.
31. Chen C., Glatt S.J., Tsuang M.T. The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. Bipolar Disord. 2008, 10(7):816-821.
32. Cichon S., Winge I., Mattheisen M., Georgi A., Karpushova A., Freudenberg J., et al. Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5'-region are associated with bipolar affective disorder. Hum. Mol. Genet. 2008, 17(1):87-97.
33. Collier D.A., Arranz M.J., Sham P., Battersby S., Vallada H., Gill P., et al. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 1996, 7(10):1675-1679.
34. Collier D.A., Stöber G., Li T., Heils A., Catalano M., Di Bella D., et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiatry 1996, 1(6):453-460.
35. Craddock N., Sklar P. Genetics of bipolar disorder. Lancet 2013, 381(9878):1654-1662.
36. Crisafulli C., Chiesa A., Han C., Lee S.J., Park M.H., Balzarro B., et al. Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262(3):199-205.
37. Davies M.A., Conley Y., Roth B.L. Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs. Biol. Res. Nurs. 2011, 13(1):55-60.
38. Davies M.A., Setola V., Strachan R.T., Sheffler D.J., Salay E., Hufeisen S.J., et al. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharm. J. 2006, 6(1):42-51.
39. Dean B., Pavey G., Thomas D., Scarr E. Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr. Res. 2006, 88(1-3):265-274.
40. Dean B., Hussain T., Hayes W., Scarr E., Kitsoulis S., Hill C., et al. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 1999, 72(4):1593-1599.
41. Dean B., Tomaskovic-Crook E., Opeskin K., Keks N., Copolov D. No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem. Int. 1999, 34(2):109-115.
42. Dean B., Opeskin K., Pavey G., Naylor L., Hill C., Keks N., et al. [3H] paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 1995, 64(3):1197-1202.
43. Del Castillo N., Zimmerman M.B., Tyler B., Ellingrod V.L., Calarge C. 759C/T variants of the serotonin (5-HT2C) receptor gene and weight gain in children and adolescents in long-term risperidone treatment. Clin. Pharmacol. Biopharm. 2013, 2(2):110.
44. De Luca V., Müller D.J., Hwang R., Lieberman J.A., Volavka J., Meltzer H.Y., et al. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum. Psychopharmacol. 2007, 22(7):463-467.
45. De Luca V., Likhodi O., Van Tol H.H., Kennedy J.L., Wong A.H. Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology 2005, 183(3):378-382.
46. Dolžan V., Serretti A., Mandelli L., Koprivsek J., Kastelic M., Plesnicar B.K. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32(6):1562-1566.
47. Dracheva S., Patel N., Woo D.A., Marcus S.M., Siever L.J., Haroutunian V. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol. Psychiatry 2008, 13(11):1001-1010.
48. Dracheva S., Elhakem S.L., Marcus S.M., Siever L.J., McGurk S.R., Haroutunian V. RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J. Neurochem. 2003, 87(6):1402-1412.
49. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 2007, 34(7):865-877.
50. Duan S., Yin H., Chen W., Xing Q., Chen Q., Guo T., et al. No association between the serotonin 1B receptor gene and schizophrenia in a case-control and family-based association study. Neurosci. Lett. 2005, 376(2):93-97.
51. Dubertret C., Hanoun N., Adès J., Hamon M., Gorwood P. Family-based association study of the serotonin-6 receptor gene (C267T polymorphism) in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 126B(1):10-15.
52. Dubertret C., Hanoun N., Adès J., Hamon M., Gorwood P. Family-based association studies between 5-HT5A receptor gene and schizophrenia. J. Psychiatr. Res. 2004, 38(4):371-376.
53. East S.Z., Burnet P.W., Kerwin R.W., Harrison P.J. An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr. Res. 2002, 57(1):15-26.
54. East S.Z., Burnet P.W., Leslie R.A., Roberts J.C., Harrison P.J. 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 2002, 45(3):191-199.
55. Ellingrod V.L., Perry P.J., Ringold J.C., Lund B.C., Bever-Stille K., Fleming F., et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 134B(1):76-78.
56. Ellingrod V.L., Miller D., Ringold J.C., Perry P.J. Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls. Psychiatr. Genet. 2004, 14(2):93-95.
57. Ellingrod V.L., Lund B.C., Miller D., Fleming F., Perry P., Holman T.L., et al. 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol. Bull. 2003, 37(2):109-112.
58. Ellingrod V.L., Perry P.J., Lund B.C., Bever-Stille K., Fleming F., Holman T.L., et al. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J. Clin. Psychopharmacol. 2002, 22(6):622-624.
59. Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W., Körner J., et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum. Genet. 1996, 97(5):614-619.
60. Erdmann J., Shimron-Abarbanell D., Cichon S., Albus M., Maier W., Lichtermann D., et al. Systematic screening for mutations in the promoter and the coding region of the 5-HT1A gene. Am. J. Med. Genet. 1995, 60(5):393-399.
61. Fan M., Liu B., Jiang T., Jiang X., Zhao H., Zhang J. Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr. Genet. 2010, 20(1):1-7.
62. Fan J.B., Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Mol. Psychiatry 2005, 10(10):928-938.
63. Fanous A.H., Neale M.C., Straub R.E., Webb B.T., O'Neill A.F., Walsh D., et al. Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. Am J Med Genet B Neuropsychiatr Genet. 2004, 125B(1):69-78.
64. Fijal B.A., Kinon B.J., Kapur S., Stauffer V.L., Conley R.R., Jamal H.H., et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharm. J. 2009, 9(5):311-318.
65. Frank B., Niesler B., Nöthen M.M., Neidt H., Propping P., Bondy B., et al. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 131B(1):1-5.
66. Fukuo Y., Kishi T., Yoshimura R., Kitajima T., Okochi T., Yamanouchi Y., et al. Serotonin 6 receptor gene and mood disorders: case-control study and meta-analysis. Neurosci. Res. 2010, 67(3):250-255.
67. Furlong R.A., Ho L., Walsh C., Rubinsztein J.S., Jain S., Paykel E.S., et al. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am. J. Med. Genet. 1998, 81(1):58-63.
68. Furlong R.A., Ho L., Rubinsztein J.S., Walsh C., Paykel E.S., Rubinsztein D.C. No association of the tryptophan hydroxylase gene with bipolar affective disorder, unipolar affective disorder, or suicidal behaviour in major affective disorder. Am. J. Med. Genet. 1998, 81(3):245-247.
69. Gatt J.M., Burton K.L., Williams L.M., Schofield P.R. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J. Psychiatr. Res. 2015, 60:1-13.
70. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet 2013, 381(9878):1672-1682.
71. Ghadirivasfi M., Nohesara S., Ahmadkhaniha H.R., Eskandari M.R., Mostafavi S., Thiagalingam S., Abdolmaleky H.M. Hypomethylation of the serotonin receptor type-2A gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B(5):536-545.
72. Gilabert-Juan J., Ivorra J.L., Tolosa A., Gratacòs M., Costas J., Sanjuán J., et al. Potential involvement of serotonin receptor genes with age of onset and gender in schizophrenia: a preliminary study in a Spanish sample. Psychiatry Res. 2011, 186(1):153-154.
73. Giusti-Rodríguez P., Sullivan P.F. The genomics of schizophrenia: update and implications. J. Clin. Invest. 2013, 123(11):4557-4563.
74. Golimbet V.E., Lavrushina O.M., Kaleda V.G., Abramova L.I., Lezheiko T.V. Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study. Eur. Psychiatry 2007, 22(3):167-170.
75. Gregoor J.G., van der Weide J., Loovers H.M., van Megen H.J., Egberts T.C., Heerdink E.R. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics 2011, 12(6):919-923.
76. Gu H., Liu C., Liu C., Chen M., Zhang Q., Zhai J., et al. The combined effects of the 5- HTTLPR and HTR1A rs6295 polymorphisms modulate decision making in schizophrenia patients. Genes Brain Behav. 2013, 12(1):133-139.
77. Gu L., Long J., Yan Y., Chen Q., Pan R., Xie X., et al. HTR2A-1438A/G polymorphism influences the risk of schizophrenia but not bipolar disorder or major depressive disorder: a meta-analysis. J. Neurosci. Res. 2013, 91(5):623-633.
78. Gupta M., Jain S., Moily N.S., Kaur H., Jajodia A., Purushottam M., et al. Genetic studies indicate a potential target 5-HTR(3B) for drug therapy in schizophrenia patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B(8):1006-1008.
79. Gutiérrez B., Arranz M.J., Huezo-Diaz P., Dempster D., Matthiasson P., Travis M., et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr. Res. 2002, 58(1):93-97.
80. Gutiérrez B., Bertranpetit J., Collier D., Arranz M.J., Vallès V., Guillamat R., et al. Genetic variation of the 5-HT2A receptor gene and bipolar affective disorder. Hum. Genet. 1997, 100(5-6):582-584.
81. Gutiérrez B., Fañanás L., Arranz M.J., Vallès V., Guillamat R., van Os J., et al. Allelic association analysis of the 5-HT2C receptor gene in bipolar affective disorder. Neurosci. Lett. 1996, 212(1):65-67.
82. Hammer C., Cichon S., Mühleisen T.W., Haenisch B., Degenhardt F., Mattheisen M., et al. Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: a European multicenter study. Transl. Psychiatry 2012, 2.
83. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav. Brain Res. 2008, 195(1):198-213.
84. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991, 48(4):355-363.
85. Hayden E.P., Nurnberger J.I. Molecular genetics of bipolar disorder. Genes Brain Behav. 2006, 5(1):85-95.
86. Hirata Y., Souza R.P., Lieberman J.A., Meltzer H.Y., Kennedy J.L. Lack of association between HTR4 gene polymorphisms and schizophrenia in case-control and family-based samples. Psychiatry Res. 2010, 175(1-2):176-178.
87. Hoehe M.R., Wendel B., Grunewald I., Chiaroni P., Levy N., Morris-Rosendahl D., et al. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders. Am. J. Med. Genet. 1998, 81(1):1-3.
88. Hong C.J., Lin C.H., Yu Y.W., Yang K.H., Tsai S.J. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001, 11(3):265-268.
89. Hranilovic D., Schwab S.G., Jernej B., Knapp M., Lerer B., Albus M., et al. Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings. Mol. Psychiatry 2000, 5(1):91-95.
90. Huang Y.Y., Battistuzzi C., Oquendo M.A., Harkavy-Friedman J., Greenhill L., Zalsman G., et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int. J. Neuropsychopharmacol. 2004, 7(4):441-451.
91. Ikeda M., Yamanouchi Y., Kinoshita Y., Kitajima T., Yoshimura R., Hashimoto S., et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9(10):1437-1443.
92. Ikeda M., Iwata N., Kitajima T., Suzuki T., Yamanouchi Y., Kinoshita Y., et al. Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology 2006, 31(4):866-871.
93. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. No association of serotonin transporter gene (SLC6A4) with schizophrenia and bipolar disorder in Japanese patients: association analysis based on linkage disequilibrium. J. Neural Transm. 2006, 113(7):899-905.
94. Inayama Y., Yoneda H., Sakai T., Ishida T., Nonomura Y., Kono Y., et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am. J. Med. Genet. 1996, 67(1):103-105.
95. Ivleva E.I., Morris D.W., Moates A.F., Suppes T., Thaker G.K., Tamminga C.A. Genetics and intermediate phenotypes of the schizophrenia-bipolar disorder boundary. Neurosci. Biobehav. Rev. 2010, 34(6):897-921.
96. Iwata N., Ozaki N., Inada T., Goldman D. Association of a 5-HT(5A) receptor polymorphism, Pro15Ser, to schizophrenia. Mol. Psychiatry 2001, 6(2):217-219.
97. Ji X., Takahashi N., Saito S., Ishihara R., Maeno N., Inada T., et al. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci. Lett. 2008, 435(2):95-98.
98. Ji X., Takahashi N., Branko A., Ishihara R., Nagai T., Mouri A., et al. An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population. Nagoya J. Med. Sci. 2008, 70(1-2):11-17.
99. Jonnakuty C., Gragnoli C. What do we know about serotonin?. J. Cell. Physiol. 2008, 217(2):301-306.
100. Jones C.A., McCreary A.C. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008, 55(6):1056-1065.
101. Jönsson E.G., Norton N., Forslund K., Mattila-Evenden M., Rylander G., Asberg M., et al. Association between a promoter variant in the monoamine oxidase A gene and schizophrenia. Schizophr. Res. 2003, 61(1):31-37.
102. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993, 8(4):315-336.
103. Kaiser R., Tremblay P.B., Schmider J., Henneken M., Dettling M., Müller-Oerlinghausen B., et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol. Psychiatry 2001, 6(2):179-185.
104. Kandel E.R. The molecular biolgogy of memory storage: a dialogue between genes and synapses. Science 2001, 294(5544):1030-1038.
105. Kawanishi Y., Harada S., Tachikawa H., Okubo T., Shiraishi H. Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia. Am. J. Med. Genet. 1998, 81(5):434-439.
106. Kiel S., Bönisch H., Brüss M., Göthert M. Impairment of signal transduction in response to stimulation of the naturally occurring Pro279Leu variant of the h5-HT7(a) receptor. Pharmacogenetics 2003, 13(2):119-126.
107. Kim Y.K., Hwang J.A., Lee H.J., Lee B.H., Na K.S. There is no association between the serotonin receptor gene and bipolar I disorder in the Korean population. Nord. J. Psychiatry 2014, 68(7):488-493.
108. Kim Y.K., Yoon H.K. Effect of serotonin-related gene polymorphisms on pathogenesis and treatment response in Korean schizophrenic patients. Behav. Genet. 2011, 41(5):709-715.
109. Kim B., Choi E.Y., Kim C.Y., Song K., Joo Y.H. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum. Psychopharmacol. 2008, 23(1):61-67.
110. Kirov G., Rees M., Jones I., MacCandless F., Owen M.J., Craddock N. Bipolar disorder and the serotonin transporter gene: a family-based association study. Psychol. Med. 1999, 29(5):1249-1254.
111. Kishi T., Yoshimura R., Fukuo Y., Okochi T., Matsunaga S., Umene-Nakano W., et al. The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(2):105-118.
112. Kishi T., Okochi T., Tsunoka T., Okumura T., Kitajima T., Kawashima K., et al. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. Psychiatry Res. 2011, 185(1-2):20-26.
113. Kouzmenko A.P., Hayes W.L., Pereira A.M., Dean B., Burnet P.W., Harrison P.J. 5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet 1997, 349(9068):1815.
114. Krzywkowski K., Davies P.A., Feinberg-Zadek P.L., Bräuner-Osborne H., Jensen A.A. High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(2):722-727.
115. Kunugi H., Ishida S., Kato T., Sakai T., Tatsumi M., Hirose T., et al. No evidence for an association of polymorphisms of the tryptophan hydroxylase gene with affective disorders or attempted suicide among Japanese patients. Am. J. Psychiatry 1999, 156(5):774-776.
116. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 1997, 2(6):457-462.
117. Kunugi H., Tatsumi M., Sakai T., Hattori M., Nanko S. Serotonin transporter gene polymorphism and affective disorder. Lancet 1996, 347(9011):1340.
118. Lai T.J., Wu C.Y., Tsai H.W., Lin Y.M., Sun H.S. Polymorphism screening and haplotype analysis of the tryptophan hydroxylase gene (TPH1) and association with bipolar affective disorder in Taiwan. BMC Med. Genet. 2005, 6:14.
119. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Wu P.L., Lu C.T., et al. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 2006, 26(2):128-134.
120. Lane H.Y., Lin C.C., Huang C.H., Chang Y.C., Hsu S.K., Chang W.H. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res. 2004, 67(1):63-70.
121. Lane H.Y., Chang Y.C., Chiu C.C., Chen M.L., Hsieh M.H., Chang W.H. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry 2002, 159(9):1593-1595.
122. Lee H.Y., Kim D.J., Lee H.J., Choi J.E., Kim Y.K. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33(2):276-280.
123. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 2003, 23(25):8788-8799.
124. Lennertz L., Wagner M., Frommann I., Schulze-Rauschenbach S., Schuhmacher A., Kühn K.U., et al. A coding variant of the novel serotonin receptor subunit 5-HT3E influences sustained attention in schizophrenia patients. Eur. Neuropsychopharmacol. 2010, 20(6):414-420.
125. Lerer B., Macciardi F., Segman R.H., Adolfsson R., Blackwood D., Blairy S., et al. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol. Psychiatry 2001, 6(5):579-585.
126. Lin C., Tang W., Hu J., Gao L., Huang K., Xu Y., et al. Haplotype analysis confirms association of the serotonin transporter (5-HTT) gene with schizophrenia in the Han Chinese population. Neurosci. Lett. 2009, 453(3):210-213.
127. López-Figueroa A.L., Norton C.S., López-Figueroa M.O., Armellini-Dodel D., Burke S., Akil H., et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 2004, 55(3):225-233.
128. Mahieu B., Souery D., Lipp O., Mendelbaum K., Verheyen G., De Maertelaer V., et al. No association between bipolar affective disorder and a serotonin receptor (5-HT2A) polymorphism. Psychiatry Res. 1997, 70(2):65-69.
129. Malhotra A.K., Goldman D., Mazzanti C., Clifton A., Breier A., Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol. Psychiatry 1998, 3(4):328-332.
130. Malhotra A.K., Goldman D., Buchanan R., Breier A., Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996, 347(9018):1830-1831.
131. Malhotra A.K., Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry 1996, 153(8):1092-1094.
132. Mann J.J., Currier D., Murphy L., Huang Y.Y., Galfalvy H., Brent D., et al. No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. J. Affect. Disord. 2008, 106(1-2):117-121.
133. Masellis M., Basile V.S., Meltzer H.Y., Lieberman J.A., Sevy S., Goldman D.A., et al. Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr. Res. 2001, 47(1):49-58.
134. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19(2):123-132.
135. Massat I., Lerer B., Souery D., Blackwood D., Muir W., Kaneva R., et al. HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study. Mol. Psychiatry 2007, 12(9):797-798.
136. Massat I., Souery D., Lipp O., Blairy S., Papadimitriou G., Dikeos D., et al. A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. Am. J. Med. Genet. 2000, 96(2):136-140.
137. Mata I., Arranz M.J., Patiño A., Lai T., Beperet M., Sierrasesumaga L., et al. Serotonergic polymorphisms and psychotic disorders in populations from North Spain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 126B(1):88-94.
138. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27(7):1159-1172.
139. Miller D.D., Ellingrod V.L., Holman T.L., Buckley P.F., Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 133B(1):97-100.
140. Minzenberg M.J., Laird A.R., Thelen S., Carter C.S., Glahn D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 2009, 66(8):811-822.
141. Mössner R., Schuhmacher A., Kühn K.U., Cvetanovska G., Rujescu D., Zill P., et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet. Genomics 2009, 19(1):91-94.
142. Muguruza C., Moreno J.L., Umali A., Callado L.F., Meana J.J., González-Maeso J. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur. Neuropsychopharmacol. 2013, 23(8):852-864.
143. Mulder H., Cohen D., Scheffer H., Gispen-de Wied C., Arends J., Wilmink F.W., et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol. 2009, 29(1):16-20.
144. Mulder H., Franke B., van der-Beek van der A.A., Arends J., Wilmink F.W., Scheffer H., et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J. Clin. Psychopharmacol. 2007, 27(4):338-343.
145. Mulder H., Franke B., van der-Beek van der A.A., Arends J., Wilmink F.W., Egberts A.C., et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharm. J. 2007, 7(5):318-324.
146. Müller D.J., Serretti A., Sicard T., Tharmalingam S., King N., Artioli P., et al. Further evidence of MAO-A gene variants associated with bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(1):37-40.
147. Mundo E., Zai G., Lee L., Parikh S.V., Kennedy J.L. The 5HT1Dbeta receptor gene in bipolar disorder: a family-based association study. Neuropsychopharmacology 2001, 25(4):608-613.
148. Naylor L., Dean B., Opeskin K., Pavey G., Hill C., Keks N., et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J. Neural Transm. 1996, 103(6):749-757.
149. Niesler B., Flohr T., Nöthen M.M., Fischer C., Rietschel M., Franzek E., et al. Association between the 5' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 2001, 11(6):471-475.
150. Niesler B., Weiss B., Fischer C., Nöthen M.M., Propping P., Bondy B., et al. Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients. Pharmacogenetics 2001, 11(1):21-27.
151. Norton N., Kirov G., Zammit S., Jones G., Jones S., Owen R., et al. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am. J. Med. Genet. 2002, 114(5):491-496.
152. Nothdurfter C., Giegling I., Konte B., Hartmann A.M., Konnerth H., Friedl M., et al. Lack of association of the 5-HT(3A) receptor with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B(3):310-315.
153. Nöthen M.M., Rietschel M., Erdmann J., Oberländer H., Möller H.J., Nober D., et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995, 346(8979):908-909.
154. Nugent A.C., Bain E.E., Carlson P.J., Neumeister A., Bonne O., Carson R.E., et al. Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression. Eur. Neuropsychopharmacol. 2013, 23(8):822-829.
155. Ohara K., Nagai M., Tani K., Tsukamoto T., Ohara K. Schizophrenia and the serotonin-2A receptor promoter polymorphism. Psychiatry Res. 1999, 85(2):221-224.
156. Ohara K., Nagai M., Tsukamoto T., Tani K., Suzuki Y., Ohara K. 5-HT2A receptor gene promoter polymorphism-1438G/A and mood disorders. Neuroreport 1998, 9(6):1139-1141.
157. Ohara K., Nagai M., Tsukamoto T., Tani K., Suzuki Y., Ohara K. Functional polymorphism in the serotonin transporter promoter at the SLC6A4 locus and mood disorders. Biol. Psychiatry 1998, 44(7):550-554.
158. Ohtsuki T., Ishiguro H., Detera-Wadleigh S.D., Toyota T., Shimizu H., Yamada K., et al. Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH genetics initiative bipolar pedigrees. Mol. Psychiatry 2002, 7(9):954-961.
159. Opgen-Rhein C., Brandl E.J., Müller D.J., Neuhaus A.H., Tiwari A.K., Sander T., et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010, 11(6):773-780.
160. Pae C.U., Artioli P., Serretti A., Kim T.S., Kim J.J., Lee C.U., et al. No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. Neurosci. Res. 2005, 52(2):195-199.
161. Peñas-Lledó E.M., Dorado P., Cáceres M.C., de la Rubia A., Llerena A. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clin. Chem. Lab. Med. 2007, 45(7):835-838.
162. Phillips M.L., Kupfer D.J. Bipolar disorder diagnosis: challenges and future directions. Lancet 2013, 381(9878):1663-1671.
163. Polsinelli G., Zai C.C., Strauss J., Kennedy J.L., De Luca V. Association and CpG SNP analysis of HTR4 polymorphisms with suicidal behavior in subjects with schizophrenia. J. Neural Transm. 2013, 120(2):253-258.
164. Preisig M., Bellivier F., Fenton B.T., Baud P., Berney A., Courtet P., et al. Association between bipolar disorder and monoamine oxidase A gene polymorphisms: results of a multicenter study. Am. J. Psychiatry 2000, 157(6):948-955.
165. Pucadyil T.J., Kalipatnapu S., Chattopadhyay A. The serotonin1A receptor: a representative member of the serotonin receptor family. Cell. Mol. Neurobiol. 2005, 25(3-4):553-580.
166. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog. Brain Res. 2008, 172:155-175.
167. Rubinsztein D.C., Leggo J., Goodburn S., Walsh C., Jain S., Paykel E.S. Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis. Hum. Mol. Genet. 1996, 5(6):779-782.
168. Qiu H.T., Meng H.Q., Song C., Xiu M.H., Chen da C., Zhu F.Y., et al. Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population. Brain Res. 2009, 1287:67-73.
169. Rajkumar A.P., Poonkuzhali B., Kuruvilla A., Srivastava A., Jacob M., Jacob K.S. Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia. Psychopharmacology 2012, 224(3):441-449.
170. Ranade S.S., Mansour H., Wood J., Chowdari K.V., Brar L.K., Kupfer D.J., et al. Linkage and association between serotonin 2A receptor gene polymorphisms and bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 121B(1):28-34.
171. Reynolds G.P., Arranz B., Templeman L.A., Fertuzinhos S., San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am. J. Psychiatry 2006, 163(10):1826-1829.
172. Reynolds G.P., Yao Z., Zhang X., Sun J., Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur. Neuropsychopharmacol. 2005, 15(2):143-151.
173. Reynolds G.P., Zhang Z., Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am. J. Psychiatry 2003, 160(4):677-679.
174. Reynolds G.P., Zhang Z.J., Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002, 359(9323):2086-2087.
175. Rietschel M., Naber D., Fimmers R., Möller H.J., Propping P., Nöthen M.M. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997, 8(8):1999-2003.
176. Rotondo A., Mazzanti C., Dell'Osso L., Rucci P., Sullivan P., Bouanani S., et al. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am. J. Psychiatry 2002, 159(1):23-29.
177. Ryu S., Cho E.Y., Park T., Oh S., Jang W.S., Kim S.K., et al. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(3):673-677.
178. Saetre P., Lundmark P., Wang A., Hansen T., Rasmussen H.B., Djurovic S., et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B(2):387-396.
179. Sáiz P.A., García-Portilla M.P., Arango C., Morales B., Alvarez V., Coto E., et al. Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(3):741-745.
180. Scarr E., Pavey G., Copolov D., Dean B. Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. Schizophr. Res. 2004, 71(2-3):383-392.
181. Schuhmacher A., Becker T., Rujescu D., Quednow B.B., Lennertz L., Wagner M., et al. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J. Psychiatr. Res. 2012, 46(8):1073-1080.
182. Schuhmacher A., Mössner R., Quednow B.B., Kühn K.U., Wagner M., Cvetanovska G., et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet. Genomics 2009, 19(11):843-851.
183. Schumacher J., Schulze T.G., Wienker T.F., Rietschel M., Nöthen M.M. Pharmacogenetics of the clozapine response. Lancet 2000, 356(9228):506-507.
184. Seifuddin F., Mahon P.B., Judy J., Pirooznia M., Jancic D., Taylor J., et al. Meta-analysis of genetic association studies on bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B(5):508-518.
185. Selvaraj S., Arnone D., Cappai A., Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci. Biobehav. Rev. 2014, 45:233-245.
186. Serretti A., Mandelli L., Giegling I., Schneider B., Hartmann A.M., Schnabel A., et al. HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(3):291-299.
187. Serretti A., Lilli R., Lorenzi C., Lattuada E., Cusin C., Smeraldi E. Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol. Psychiatry 2002, 7(1):95-99.
188. Serretti A., Cristina S., Lilli R., Cusin C., Lattuada E., Lorenzi C., et al. Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. Am. J. Med. Genet. 2002, 114(4):361-369.
189. Serretti A., Cusin C., Lorenzi C., Lattuada E., Lilli R., Smeraldi E. Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. Am. J. Med. Genet. 2000, 96(1):84-87.
190. Shi J., Gershon E.S., Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 2008, 104(1-3):96-107.
191. Shimron-Abarbanell D., Harms H., Erdmann J., Albus M., Maier W., Rietschel M., et al. Systematic screening for mutations in the human serotonin 1F receptor gene in patients with bipolar affective disorder and schizophrenia. Am. J. Med. Genet. 1996, 67(2):225-228.
192. Shinkai T., Ohmori O., Kojima H., Terao T., Suzuki T., Abe K. Association study of the 5-HT6 receptor gene in schizophrenia. Am. J. Med. Genet. 1999, 88(2):120-122.
193. Shiroiwa K., Hishimoto A., Mouri K., Fukutake M., Supriyanto I., Nishiguchi N., et al. Common genetic variations in TPH1/TPH2 genes are not associated with schizophrenia in Japanese population. Neurosci. Lett. 2010, 472(3):194-198.
194. Sodhi M.S., Burnet P.W., Makoff A.J., Kerwin R.W., Harrison P.J. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol. Psychiatry 2001, 6(4):373-379.
195. Sodhi M.S., Arranz M.J., Curtis D., Ball D.M., Sham P., Roberts G.W., et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995, 7(1):169-172.
196. Souery D., Van Gestel S., Massat I., Blairy S., Adolfsson R., Blackwood D., et al. Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. Biol. Psychiatry 2001, 49(5):405-409.
197. Souza R.P., de Luca V., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet. Genomics 2010, 20(4):274-276.
198. Stöber G., Heils A., Lesch K.P. Serotonin transporter gene polymorphism and affective disorder. Lancet 1996, 347(9011):1340-1341.
199. Sullivan G.M., Ogden R.T., Oquendo M.A., Kumar J.S., Simpson N., Huang Y.Y., et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol. Psychiatry 2009, 66(3):223-230.
200. Sumiyoshi T., Tsunoda M., Higuchi Y., Itoh T., Seo T., Itoh H., et al. Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv. Ther. 2010, 27(5):307-313.
201. Sun J., Jayathilake K., Zhao Z., Meltzer H.Y. Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia. Psychiatry Res. 2012, 198(2):202-206.
202. Suzuki T., Iwata N., Kitamura Y., Kitajima T., Yamanouchi Y., Ikeda M., et al. Association of a haplotype in the serotonin 5-HT4 receptor gene (HTR4) with Japanese schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 121B(1):7-13.
203. Syagailo Y.V., Stöber G., Grässle M., Reimer E., Knapp M., Jungkunz G., et al. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am. J. Med. Genet. 2001, 105(2):168-171.
204. Takekita Y., Fabbri C., Kato M., Nonen S., Sakai S., Sunada N., et al. HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia. J. Clin. Psychopharmacol. 2015, 35(3):220-227.
205. Tauscher J., Kapur S., Verhoeff N.P., Hussey D.F., Daskalakis Z.J., Tauscher-Wisniewski S., et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch. Gen. Psychiatry 2002, 59(6):514-520.
206. Tee S.F., Chow T.J., Tang P.Y., Loh H.C. Linkage of schizophrenia with TPH2 and 5-HTR2A gene polymorphisms in the Malay population. Genet. Mol. Res. 2010, 9(3):1274-1278.
207. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet. Genomics 2005, 15(4):195-200.
208. Theisen F.M., Hinney A., Brömel T., Heinzel-Gutenbrunner M., Martin M., Krieg J.C., et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr. Genet. 2004, 14(3):139-142.
209. Tsai S.J., Hong C.J., Yu Y.W., Lin C.H. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360(9347):1790.
210. Tsai S.J., Hong C.J., Yu Y.W., Lin C.H., Song H.L., Lai H.C., et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr. Res. 2000, 44(3):177-181.
211. Tsai S.J., Chiu H.J., Wang Y.C., Hong C.J. Association study of serotonin-6 receptor variant (C267T) with schizophrenia and aggressive behavior. Neurosci. Lett. 1999, 271(2):135-137.
212. Tut T.G., Wang J.L., Lim C.C. Negative association between T102C polymorphism at the 5-HT2A receptor gene and bipolar affective disorders in Singaporean Chinese. J. Affect. Disord. 2000, 58(3):211-214.
213. Ujike H., Nomura A., Morita Y., Morio A., Okahisa Y., Kotaka T., et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry 2008, 69(9):1416-1422.
214. Van Den Bogaert A., Sleegers K., De Zutter S., Heyrman L., Norrback K.F., Adolfsson R., et al. Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. Arch. Gen. Psychiatry 2006, 63(10):1103-1110.
215. Vázquez-Bourgon J., Arranz M.J., Mata I., Pelayo-Terán J.M., Pérez-Iglesias R., Medina-González L., et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res. 2010, 175(3):189-194.
216. Vincent J.B., Masellis M., Lawrence J., Choi V., Gurling H.M., Parikh S.V., et al. Genetic association analysis of serotonin system genes in bipolar affective disorder. Am. J. Psychiatry 1999, 156(1):136-138.
217. Vogt I.R., Shimron-Abarbanell D., Neidt H., Erdmann J., Cichon S., Schulze T.G., et al. Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia. Am. J. Med. Genet. 2000, 96(2):217-221.
218. Wang L., Fang C., Zhang A., Du J., Yu L., Ma J., et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol. 2008, 22(8):904-909.
219. Wang L., Yu L., He G., Zhang J., Zhang A.P., Du J., et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci. Lett. 2007, 414(1):1-4.
220. Watanabe Y., Nunokawa A., Kaneko N., Someya T. The tryptophan hydroxylase 1 (TPH1) gene and risk of schizophrenia: a moderate-scale case-control study and meta-analysis. Neurosci. Res. 2007, 59(3):322-326.
221. Wei Z., Wang L., Xuan J., Che R., Du J., Qin S., et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33(3):547-551.
222. Williams J., Spurlock G., McGuffin P., Mallet J., Nöthen M.M., Gill M., et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) group. Lancet 1996, 347(9011):1294-1296.
223. Yasuno F., Suhara T., Ichimiya T., Takano A., Ando T., Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol. Psychiatry 2004, 55(5):439-444.
224. Yevtushenko O.O., Cooper S.J., O'Neill R., Doherty J.K., Woodside J.V., Reynolds G.P. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry 2008, 192(6):424-428.
225. Yu Y.W., Tsai S.J., Lin C.H., Hsu C.P., Yang K.H., Hong C.J. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999, 10(6):1231-1233.
226. Zaboli G., Jönsson E.G., Gizatullin R., Asberg M., Leopardi R. Tryptophan hydroxylase-1 gene variants associated with schizophrenia. Biol. Psychiatry 2006, 60(6):563-569.
227. Zhang X.N., Jiang S.D., He X.H., Zhang L.N. 102T/C SNP in the 5-hydroxytryptamine receptor 2A (HTR2A) gene and schizophrenia in two southern Han Chinese populations: lack of association. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 126B(1):16-18.